and Vincent Marks BM MRCPE (Area Laboratory, Epsom, Surrey) Occasionally hypoglycemia may be incapacitating and refractory to treatment in adults or children.
When the cause of recurrent hypoglycwmia cannot be corrected, as in metastatic islet cell tumour, hepatogenous hypoglycwmia or glycogen storage disease, or is poorly understood, as in idiopathic hypoglycemia of childhood, most available methods of treatment (Table 1) are far from satisfactory. Restriction of dietary leucine, when applicable, is expensive and, to obtain Table I Therapy in severe recurrent fasting hypoglyciemia (1) Correction ofknown cause: e.g. insulinoma (2) Diet: (a) Causal, e.g. avoid fructose, galactose.
(b) Low-leucine diet. (c) Glucose supplements (3) Corticosteroids or ACTH (4) Human growth hormone (5) Glucagon (6) Adrenaline or ephedrine (7) Alloxan (8) Partial or total pancreatectomy (9) Diazoxide effective results, its exclusion from the diet may have to be so strict that malnutrition ensues. In our experience, corticosteroids and ACTH are at best, only temporarily palliative and frequently cause undesirable side effects; glucagon, adrenaline, ephedrine, alloxan or partial pancreatectomy are ineffective and may do harm. When hypoglycemic subjects are subjected to a total pancreatectomy, the ensuing metabolic instability may be extraordinarily difficult to control.
It is in the light of this choice that we are evaluating the place of diazoxide in the management of intractable hypoglycemia.
Diazoxide, a heterocyclic compound, was originally introduced by the Schering Corporation (USA) as an anti-hypertensive, non-diuretic, benzothiadiazine and its hyperglyctmic action was initially regarded as an unwelcome side-effect. After Dollery et al. (1962) reported that diazoxide, especially when combined with the diuretic benzothiadiazines, induced severe diabetes mellitus, it was no longer used as an anti-hypertensive drug.
Subsequent animal studies showed that diazoxide was superior to other benzothiadiazines as a hyperglycwmic agent and that its hyperglycemic effect was potentiated by other benzothiadiazines (Wolff & Parmley 1963) .
In 1964 Drash & Wolff reported that, year-old boy with leucine sensitive hypoglycTmia, diazoxide in doses of 12 mg/kg/day abolished symptoms of neuroglycopenia, elevated the blood glucose response to oral glucose, but did not improve fasting hypoglycemia. The value of diazoxide alone (Marks et al. 1965) or in combination with other benzothiadiazines (Lundvall & Johnsson 1965 , Ernesti et al. 1965 in the management of intractable hypoglycemia due to malignant insulinoma, has recently been described. The present report presents the results of diazoxide therapy in one adult and three children, with hypoglycaemia due to different causes.
Case 1 HT, a 51-year-old male with metastatic insulinoma had incapacitating recurrent hypoglycemia which had failed to improve on corticosteroids. For the past year normoglycemia has been maintained with diazoxide, 200 mg b.d. The patient is subjectively fit, and leads a full working life. Side effects of diazoxide, i.e. dependent cedema and increased hair growth on limbs and trunk, were mild, appearing soon after treatment and lasting for only two to three months.
Case 2 P C, a plump male infant presented at the Mayday Hospital, Croydon at the age of 2 months with convulsions and a blood sugar concentration of 15 mg/100 ml. Delivery was normal at full term and he weighed 4 65 kg (10 lb 4 oz) at birth. There was no family history of diabetes. It was found (Dr J H Burkinshaw) that casein abolished the rise in blood sugar after oral sucrose and that symptoms appeared to improve on a low leucine diet. However, fasting blood sugar levels remained low (12-17 mg/100 ml) and biochemical hypoglycemia was invariable two to three hours after meals. Plasma insulin levels (15-28 ,uU/ml), although not high in absolute terms, were excessive for the level of blood sugar (17-29 mg/l00 ml).
Symptoms recurred at the age of six months and he was referred to the Royal Free Hospital as a case of idiopathic hypoglycmemia of infancy for a trial of diazoxide therapy. While still on a low leucine diet (622 mg L-leucine/day) he was given diazoxide, 25 mg twice daily (body weight 10 kg), but this had little or no effect even when a further 25 mg of diazoxide was added. Severe 'fasting' hypoglycemia (7-12 mg/100 ml) persisted ( Fig 1) and he was still unable to tolerate more than three hours without food. After two weeks chlorothiazide 100 mg b.d. was added to potentiate the hyperglycemic effect of diazoxide (Fig 1) . By the following day there was a striking rise in blood glucose. On this regime normoglycmemia was main- Blood glucose levels at intervals during the day, before and after feeds, varied between 60-83 mg/100 ml, and showed the absence of a diabetic state. Intravenous glucose tests showed ( Fig 2) an extremely rapid rate of glucose disappearance before therapy, with conversion to normal on diazoxide-chlorothiazide therapy.
Fasting plasma insulin levels were lower (8-10 ,U/ml) on therapy, despite the higher blood glucose levels. A tolbutamide test (Fig 3) performed during treatment showed an excessive, and abnormally prolonged, decrease in blood glucose, although the insulin response was normal. During treatment the glucose responses to L-leucine and to glucagon were normal.
On the diazoxide-chlorothiazide regime an apathetic, floppy baby became alert. Before therapy the EEG showed a moderately diffuse abnormality with some asymmetry suggesting underlying cerebral damage. On treatment serial EEGs progressively improved to within normal limits.
The fasting blood glucose was 75 mg/100 ml two months after discharge from the hospital and a striking growth of downy hair over the face, limbs and back (particularly the nape of the neck and sacral area) was apparent. This abnormal hair growth appeared to stop after a further two months. Urinary 17-ketosteroids and 17-hydroxycorticosteroids were within normal limits. On readmission at the age of 11 months he was found to have fasting hypoglycemia again, and the dosage of diazoxide (50 mg morning, 100 mg at night) and chlorothiazide (200 mg b.d.) was increased to restore fasting normoglycwmia. Case 3 P le P, a plump male infant aged 5 months, normal delivery at term. Birth weight was 4-25 kg. He presented with convulsions and hypoglycemia, and severe leucine sensitivitythe blood glucose concentration falling from a fasting level of 54 mg/100 ml to 3 mg/100 ml at 45 minuteswas found (Dr D A J Williamson). On a low leucine diet, blood glucose remained low (25-45 mg/100 ml) and he was referred to the Royal Free Hospital as a case of leucinesensitive idiopathic hypoglycaemia of infancy for a trial of diazoxide therapy.
While the low leucine diet was continued, the fasting blood glucose varied between40-55 mg/100 ml. On two occasions blood glucose measurements were made during and after a regular milk feed which was part of his diet. On each occasion the blood glucose level fell from a prefeed value of 52-55 mg/100 ml to less than 35 mg/100 ml (Fig 4) . In contrast to Case 2, the rate of disappearance of intravenous glucose was normal ( Fig 5) . On diazoxide therapy (25 mg in the morning, 50 mg at night, body weight 10 kg) fasting blood glucose values increased (62-75 mg/100 ml) and the milk feed produced a riseinblood glucose (Fig4) . A normal diet was well tolerated and normal fasting and post-prandial blood glucose values were maintained on diazoxide 50 mg twice a day. Although mild leucine sensitivity could still be demonstrated during diazoxide therapy (Fig 6) , the amount of leucine present in the normal diet was insufficient to lower the blood glucose while on diazoxide therapy.
Case 4 M A, a 5-year-old male Egyptian child with type 3 glycogen storage disease (debranching enzyme defect).
The fasting blood sugar was persistently low, rising after oral fructose, but not after glucagon unless given shortly after a meal. He had been treated for a year on alternate daily glucagon injections, but had experienced seven hypoglycemic comas. Increasing the frequency of glucagon injections was ineffective, but attacks were alleviated by an extra meal after midnight.
On examination he had marked truncal obesity (weight 21 kg, height 1 metre) and a huge, firm, smooth liver. During a brief trial of diazoxide (100 mg twice a day) the fasting blood glucose rose from 20-30 mg/100 ml before treatment to 40-85 mg/100 ml after treatment. A second trial of diazoxide (200 mg twice a day) produced a similar increase in fasting blood glucose (70-85 mg/100 ml) which was maintained for three days. We were about to reduce the dose of diazoxide because of anorexia and nausea, when the patient suddenly returned to Egypt.
When commencing diazoxide therapy we have been guided by anorexia, nausea and vomiting as signs of excessive dosage, whilst trying to achieve an effective loading dose. Frequent samplings for blood glucose estimations were made to ensure that hyperglycemia did not occur.
Although hypotension, excessive sodium retention, potassium deficiency and hyperuricemia are potential hazards, the only undesirable sideeffects, apart from gastrointestinal symptoms, encountered by us with diazoxide have been temporary sodium retention, mild cedema and increased hair growth. These side effects have not previously been described. In view of unreported experience elsewhere, we believe that diazoxide therapy is still experimental and requires careful supervision.
The hyperglyctmic effect of diazoxide probably depends on several mechanisms. Reduction of insulin secretion, shown in two of our patients, is one contributing factor. In addition we have evidence that, during diazoxide therapy, peripheral glucose utilization was impaired by an intracellular block in glucose metabolism, because diazoxide not only slowed the rate of glucose disappearance but also increased the volume of distribution of glucose. While there is some evidence that diazoxide may increase hepatic glucose release, the elevation of the fasting blood sugar in glycogen storage disease (debranching enzyme deficiency) showed that diazoxide is effective even when hepatic glycogenolysis is severely impaired. Other studies have implied that high doses of potassium or f-adrenergic blocking agents will diminish the hyperglycmmic effect of diazoxide in normal man or animals (Staquet et al. 1965 ).
Summary
Diazoxide is an experimental drug of value in the treatment of intractable hypoglycemia but more long term experience is required to define its place in therapy. However, its place in the management of hypoglycemia due to malignant insulinoma and non-islet cell tumours is established (Marks & Samols 1966) . There is sufficient evidence that in infants with different types of idiopathic hypoglycemia the advantages of diazoxide outweigh its mild side effects. Brief trials of diazoxide in glycogen storage disease were surprisingly encouraging. We conclude that diazoxide therapy should be considered in the management of all cases of severe recurrent fasting hypoglycwmia when the cause is not amenable to other treatment. Medes (1932) . A 49-year-old man with myasthenia gravis appeared to lack the enzyme p-hydroxyphenylpyruvate hydroxylase and, in consequence, excreted in his urine large amounts ofp-hydroxyphenylpyruvic acid (p-HPPA) and the related substances tyrosine and p-hydroxyphenyl-lactic acid (p-HPLA). Over the past fifteen years it has become apparent that a similar enzymic defect occurs in some children who present with hepatic and renal tubular dysfunction.
Of the seven patients investigated by the author, one (first seen in 1950) presents the 'typical' clinical and biochemical picture. At 2 years 3 months this girl presented with rickets that did not respond to vitamin D and very marked hepatomegaly (first noted at the age of 10 months). There was severe and intractable renal acidosis, gross generalized aminoaciduria, glucosuria, fructosuria and moderate proteinuria. The child's urine consistently contained tyrosine, p-HPPA, p-HPLA and related phenolic acids in very large amounts, suggesting absence or inactivity of p-hydroxyphenylpyruvate hydroxylase. The child died at the age of 7 years 3 months and, at necropsy, multilobular hepatic cirrhosis was found. The term 'congenital hepatic and renal dysfunction' was coined for this condition (Woolf 1961 (Woolf , 1962 (Woolf , 1963 and later changed to 'inborn hepato-renal dysfunction' (Woolf 1966). Similar cases have been described by van Creveld (1934) (1964), Gentz et al. (1965) and Tanagushi & Gjessing (1965) . Most of these patients died before puberty.
Of the other 6 patients investigated by the author, 5 presented withjaundice and an enlarging liver within a few days or weeks of birth; the sixth failed to gain weight or feed satisfactorily, had a bleeding tendency, was found to have a prothrombin level only 16% to 23% of normal and had an enlarging liver. Five of these 6 children died aged, respectively, 1 week, 3i, 71, 101 and 13 weeks. All showed evidence of renal tubular failure to reabsorb aminoacids and/or glucose; where they were looked for, tyrosine, p-HPPA and p-HPLA were found in the urine in large amounts. 
